Filtered By:
Condition: Thrombosis
Procedure: Hemodialysis
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 192 results found since Jan 2013.
Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study
Conclusion: A significant increase in hemorrhagic events by the use of dual or more AP agents and by co-administration of an AP agent and WF in patients on HD should be considered in planning their anti-thrombosis regimen.Kidney Blood Press Res 2017;42:553 –564
Source: Kidney and Blood Pressure Research - September 18, 2017 Category: Urology & Nephrology Source Type: research
Asymptomatic Plaques of Lower Peripheral Arteries and Their Association with Cardiovascular Disease: An Autopsy Study.
CONCLUSION: These results indicate that asymptomatic advanced plaques are frequently observed in common iliac arteries, and are associated with generalized atherosclerosis and CVD events.
PMID: 28367862 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - April 5, 2017 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
ConclusionsThe prevalence of AF is high amongst HD patients and is associated with age, sex, and distinct comorbidities. Practice patterns of antithrombotic treatment indicate a lack of consensus for stroke prevention in HD patients with AF.
Source: PLoS One - January 3, 2017 Category: Biomedical Science Authors: Oliver K önigsbrügge Source Type: research
Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment
ConclusionApixaban appears to be a reasonable alternative to warfarin in patients with severe renal impairment.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 31, 2016 Category: Drugs & Pharmacology Authors: Brooke E. Stanton, Naomi S. Barasch, Katie B. Tellor Tags: Original Research Article Source Type: research
A comparison of red blood cell transfusion utilization between anti-factor Xa and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
CONCLUSION: Anti-Xa was associated with a significant reduction in RBC transfusions when compared to patients monitored by aPTT alone. This article is protected by copyright. All rights reserved.
PMID: 27543785 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 19, 2016 Category: Hematology Authors: Belk KW, Laposata M, Craver C Tags: J Thromb Haemost Source Type: research
A comparison of red blood cell transfusion utilization between anti ‐factor Xa and activated partial thromboplastin monitoring in patients receiving unfractionated heparin
ConclusionAnti‐Xa was associated with a significant reduction in RBC transfusions when compared to patients monitored by aPTT alone.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 30, 2016 Category: Hematology Authors: K.W. Belk, M. Laposata, C. Craver Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
Direct oral anticoagulant associated bleeding.
Abstract
Direct oral anticoagulants (DOAC) are recommended for stroke prevention in atrial fibrillation and for the treatment of venous thromboembolism. However, they are associated with hemorrhagic complications. Management of DOAC-induced bleeding remains challenging. Activated or non-activated prothrombin concentrates are proposed, although their efficacy to reverse DOAC is uncertain. Therapeutic options also include antidotes: idarucizumab, antidote for dabigatran, has been approved for use whereas andexanet alpha, antidote for anti-Xa agents, and aripazine, antidote for all DOAC, are under development. Other ...
Source: Journal des Maladies Vasculaires - June 9, 2016 Category: Cardiology Authors: Godier A, Martin AC, Rosencher N, Susen S Tags: J Mal Vasc Source Type: research
French Intensive Care Society, International congress - Réanimation 2016.
C, Sauneuf B, Verrier P, Pottier V, Orabona M, Samba D, Viquesnel G, Lermuzeaux M, Hazera P, Hanouz JL, Parienti JJ, Du Cheyron D, Demoule A, Clavel M, Rolland-Debord C, Perbet S, Terzi N, Kouatchet A, Wallet F, Roze H, Vargas F, Guérin C, Dellamonica J, Jaber S, Similowski T, Quenot JP, Binquet C, Vinsonneau C, Barbar SD, Vinault S, Deckert V, Lemaire S, Hssain AA, Bruyère R, Souweine B, Lagrost L, Adrie C, Jung B, Daurat A, De Jong A, Chanques G, Mahul M, Monnin M, Molinari N, Lheureux O, Trepo E, Hites M, Cotton F, Wolff F, Surin R, Créteur J, Vincent JL, Gustot T, Jacobs F, Taccone FS, Neuville M, Timsit JF, El-Hel...
Source: Australian Family Physician - May 31, 2016 Category: Primary Care Authors: Jaillette E, Girault C, Brunin G, Zerimech F, Chiche A, Broucqsault-Dedrie C, Fayolle C, Minacori F, Alves I, Barrailler S, Robriquet L, Delaporte E, Thellier D, Delcourte C, Duhamel A, Nseir S, Valette X, Desmeulles I, Savary B, Masson R, Seguin A, Daubi Tags: Ann Intensive Care Source Type: research
Retrograde Thromboembolism to Basilar Artery During Arteriovenous Graft Thrombectomy (P4.353)
Conclusion: This case suggests that the use of thrombectomy devices that alter hydrodynamics within the arterial circulation can result in retrograde emboli and stroke. Rapid treatment of ischemic strokes can minimize long-term morbidity and mortality.Disclosure: Dr. Salahuddin has nothing to disclose. Dr. Jumaa has nothing to disclose. Dr. Tietjen holds stock and/or stock options in Johnson & Johnson and Stryker. Dr. Zaidi has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Salahuddin, H., Jumaa, M., Tietjen, G., Zaidi, S. Tags: Cerebrovascular Case Reports Source Type: research
Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
CONCLUSIONS: We found no evidence to assess the benefits and harms of early versus delayed EPO for the anaemia of ESKD.
PMID: 26671531 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 16, 2015 Category: Journals (General) Authors: Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G Tags: Cochrane Database Syst Rev Source Type: research
Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
This study simulated the dose-exposure relationship of dabigatran in patients undergoing haemodialysis. Dabigatran exposure was modelled at once- and twice-daily doses of 75 mg, 110 mg and 150 mg and at variations in non-renal clearance and dialysis settings. Resultant dose exposure (area under the curve [AUC]) was compared with values simulated from typical patients in the RE-LY® trial (based on a previously characterised pharmacometric model). In this simulation, all twice-daily dosages resulted in exposures above those simulated from typical RE-LY patients (1.5- to 3.3-fold increase in AUC) and thus may not be optimal ...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Liesenfeld KH, Clemens A, Kreuzer J, Brueckmann M, Schulze F Tags: Thromb Haemost Source Type: research
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
CONCLUSIONS: In patients with dabigatran associated bleeding, RRT appears to be effective in reducing dabigatran concentrations and in case reports this has been associated with a reduction in duration and/or severity of bleeding. However, a rebound in concentrations may be seen following withdrawal of RRT suggesting that a prolonged course of RRT may be more effective. This article is protected by copyright. All rights reserved.
PMID: 26270886 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 13, 2015 Category: Hematology Authors: Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M Tags: J Thromb Haemost Source Type: research
Hemodialysis for the treatment of dabigatran‐associated bleeding: a case report and systematic review
ConclusionsIn patients with dabigatran associated bleeding, RRT appears to be effective in reducing dabigatran concentrations and in case reports this has been associated with a reduction in duration and/or severity of bleeding. However, a rebound in concentrations may be seen following withdrawal of RRT suggesting that a prolonged course of RRT may be more effective.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - August 1, 2015 Category: Hematology Authors: Chatree Chai‐Adisaksopha, Christopher Hillis, Wendy Lim, Kochawan Boonyawat, Karen Moffat, Mark Crowther Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation
Conclusions
In our population of HD patients with AF, the mortality is very high. OAT is not associated with increased mortality, while antiplatelet drugs are. OAT seems, on the contrary, associated with a better survival; however, it does not decrease the incidence of ischaemic stroke, whereas it increases the incidence of bleeding. Bleeding risk is lower in subjects in whom the INR is kept within the therapeutic range.
Source: Nephrology Dialysis Transplantation - February 23, 2015 Category: Urology & Nephrology Authors: Genovesi, S., Rossi, E., Gallieni, M., Stella, A., Badiali, F., Conte, F., Pasquali, S., Bertoli, S., Ondei, P., Bonforte, G., Pozzi, C., Rebora, P., Valsecchi, M. G., Santoro, A. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research
Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man
Dabigatran is an oral direct inhibitor indicated for stroke prevention in patients with atrial fibrillation. Unlike warfarin, dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that laboratory test and dose adjustments are not necessary; nevertheless, circumstances of excessive anticoagulation, decreased kidney function, and instances of significant bleeding and thrombosis require laboratory assessment. In order to gather experience in the management of global [activated partial thromboplastin time (APTT) and thrombin time (TT) with extended endpoint] and specific [ecarin chromogenic assa...
Source: Blood Coagulation and Fibrinolysis - January 30, 2015 Category: Hematology Tags: Case Reports Source Type: research
